Table 4 Subgroup analysis of medical expenditure for lung cancer diagnosis and treatment per case, Price in 2019
From: Medical expenditure for lung cancer in China: a multicenter, hospital-based retrospective survey
Variable | Expenditure per case during 2002–2011, CNY Mean (95% CI) | Value | P | Expenditure per case during 2009–2011, CNY Mean (95% CI) | Value | P |
|---|---|---|---|---|---|---|
Overall | 49,432(48,654–50,210) | 56,773(55,312–58,233) | ||||
Region | 378.00 | < 0.001a | 223.69 | < 0.001a | ||
East | 54,607(53,448–55,767) | 65,142(62,997–67,287) | ||||
Central | 58,473(55,805–61,142) | |||||
West | 40,478(46,897–49,403) | 41,100(38,450–43,751) | ||||
Hospital type | − 17.94 | < 0.001b | − 4.61 | < 0.001b | ||
General hospital | 40,598(39,345–41,850) | 54,712(52,113–57,309) | ||||
Specialized hospital | 53,249(52,284–54,215) | 57,822(56,058–21,576) | ||||
Hospital level | 19.95 | < 0.001b | 14.83 | < 0.001b | ||
3A | 50,899(50,085–51,713) | 58,525(57,015–60,034) | ||||
3A less | 29,453(27,186–31,718) | 23,642(19,905–27,381) | ||||
Number of clinical visits per case | 1671.52 | < 0.001a | 408.03 | < 0.001a | ||
1 | 30,243(29,622–30,864) | 33,824(32,559–35,087) | ||||
2 | 58,239(56,293–60,184) | 60,826(57,365–64,286) | ||||
3 | 75,174(72,428–77,919) | 75,352(70,773–79,931) | ||||
4 + | 90,366(88,008–92,723) | 89,193(85,739–92,646) | ||||
Gender | 6.18 | < 0.001b | 1.57 | 0.116b | ||
Male | 50,724(49,777–51,673) | 57,376(55,602–58,027) | ||||
Female | 46,434(45,082–47,785) | 55,452(52,874–58,027) | ||||
Age at diagnosis, y | 8.35 | < 0.001a | 9.41 | < 0.001a | ||
< 45 | 48,397(45,878–50,916) | 55,431(50,111–60,751) | ||||
45–54 | 49,669(48,036–51,302) | 60,044(56,693–63,396) | ||||
55–64 | 50,856(49,502–52,211) | 58,647(56,256–61,039) | ||||
≥ 65 | 48,232(46,912–49,552) | 53,407(50,979–55,834) | ||||
Pathological type | 67.80 | < 0.001b | 32.21 | < 0.001b | ||
Squamous cell carcinoma | 49,608(48,385–50,831) | 60,171(57,660–62,682) | ||||
Adenocarcinoma | 55,008(53,569–56,447) | 64,228(61,672–66,784) | ||||
Others | 46,694(45,039–48,350) | 54,337(51,008–57,616) | ||||
Clinical stage | 21.03 | < 0.001a | 21.81 | < 0.001a | ||
I | 46,135(44,734–47,538) | 54,430(51,719–57,143) | ||||
II | 46,515(44,797–48,235) | 55,559(52,033–59,087) | ||||
III | 52,034(50,562–53,508) | 58,106(55,436–60,775) | ||||
IV | 50,558(49,025–52,093) | 54,372(51,571–57,173) |